Zohydro's potential competitors starting to nip at its heels

|By:, SA News Editor

Teva Pharmaceutical Industries (TEVA) reports positive Phase 3 results for its hydrocodone bitartrate (CEP-33237) extended-release tablets for lower back pain.

Patients were dosed at 30mg - 90mg every 12 hours. Their degree of pain was measured by weekly average Worst Pain Intensity (WPI) and weekly Average Pain Intensity (API) scores.

The study utilized a randomized withdrawal design to evaluate the safety and efficacy of the drug. After randomization, all patients who continued to receive CEP-33237 maintained their improved WPI scores. Patients who received the placebo had significantly worse scores.

The product is acetaminophen-free and contains abuse-deterrent properties.

The company plans to submit its NDA to the FDA by the end of the year.

(ZGNX)